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The efficacy of addition of dexmedetomidine to 
intrathecal bupivacaine in lower abdominal surgery 
under spinal anesthesia 
 
Abstract 
Background: Spinal anesthesia is the common choice for anesthesia in lower abdomen 
surgery and intrathecal adjutants have gained popularity with the aim of prolonging the 
duration of block, quality of block and post operation pain control. The purpose of this 
study was to evaluate the effects of adding dexmedetomidine to hyperbaric bupivacaine in 
lower abdominal surgery under spinal anesthesia. The main outcomes were considered 
pain score, duration of analgesia, hemodynamic changes and adverse side effects like 
nausea and vomiting. 
Methods: This double-blind randomized clinical trial was conducted on one hundred 
patients between 18 to 65 years old scheduled for lower abdominal surgery. Fifty patients 
were randomly allocated to receive either 12.5mg hyperbaric bupivacaine (2.5cc) plus 
5µgr dexmedetomidine (0.5cc) intrathecally while fifty patients received either 12.5mg 
hyperbaric bupivacaine (2.5cc) and 0.5cc Saline 0.9% intrathecally. 
Results: Vital sign parameters like heart rate, blood pressure and oxygen saturation levels 
were registered in the normal range in both groups. The average duration of the onset of 
pain (230±86 min) in bupivacaine group was significantly (p≤0.000) less than 
dexmedetomidine group (495±138 minutes). The severity of pain at all times in 
dexmedetomidine group was significantly (p<0.05) less than bupivacaine group. The 
severity of shivering and the number of patients who needed treatment for nausea and 
vomiting in dexmedetomedine group has been less in comparison to bupivacaine. 
Conclusion: We concluded that intrathecal dexmedetomidine increases the duration of 
analgesia and reduces postoperative pain without changes in the hemodynamic parameters 
and adverse side effects. It can be considered as an appropriate adjuvant to intrathecal local 
anesthetics for lower limb surgeries. 
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Postoperative pain is a major concern for patients and postoperative pain 
management is considered as a part of perioperative care (1). Lower abdominal surgeries 
became popular under neuraxial block because it is a cost-effective method and an easy-to-
perform technique (2, 3). Spinal anesthesia is still the first option, due to having rapid 
onset, superior blockade with a lower failure rate but it is associated with such drawbacks 
as shorter duration of the block, short-term anesthetic effect, and the onset of pain after the 
absorption of the drug (2). Different adjuvant can be used, along with local anesthetics for 
spinal anesthesia to relieve pain during operation and provide long-term postoperative 
analgesia (3).  
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Alpha receptor agonists are added to local anesthetics as 
an adjuvant to improve their effects and reduce the required 
dose of anesthetics (4). Dexmedetomidine is a selective α2 
agonist that is 1,600 times more selective for the alpha-2 
receptor than the alpha-1 receptor (1, 5). This drug has anti-
anxiety, sedative, analgesic, and sympatholytic effects with 
minimum respiratory depression (6-8). This study aimed to 
investigate the effect of intrathecal dexmedetomidine with 
local anesthetic on analgesic duration during and after the 
operation. 
 
 
Methods 
In this double-blind randomized controlled trial study in 
2013, 100 patients aged between 18 and 65 years, in ASA 
(American Society of Anesthesiologists) class I, II and 
candidate for elective lower abdominal surgery, such as 
prostatectomy, varicocelectomy, hysterectomy, and inguinal 
herniorrhaphy, were included after obtaining their informed 
consent in Shahid Beheshti Hospital in Babol. This study 
was registered in the Clinical Trial Registration Center of 
Iran under the code IRCT201310293305N6. Patients with a 
history of cardiovascular diseases, dyspnea, diabetes, and 
renal or liver complications, patients with a history of taking 
narcotics, antiepileptic drugs, antipsychotics, and/or 
analgesics, and patients with a history of consuming alcohol 
were excluded.  
In addition, patients with severe pain at the operation site 
during surgery, which necessitated general anesthesia, were 
removed from the study. Sample size calculation was 
performed on Hong study’s result (9) and its related formula 
for sample size in a=0.05 and β=0.8. Patients were divided 
into two 50-member groups using simple random sampling 
technique by a resident anesthesiologist. For allocation 
concealment, we used opaque pocket. The case group 
received dexmedetomidine+bupivacaine (Marcaine); 
whereas, the control group only received Marcaine. After 
transferring the patients to the procedure table, standard 
monitoring systems, including ECG, NIBP, and SPO2 were 
connected to them.  
Then, Ringer's serum (5 ml per kilogram body weight) 
was administered through intravenous cannulation. After 
measuring HR, BP, and SPO2 (as basic measurements), 
patients were placed in a sitting position, and prepping and 
draping were conducted. Then, the case group received 
intrathecal injection of 2.5 ml of bupivacaine (0.5%) and 0.5 
ml of dexmedetomidine (5μg); whereas, the control group 
received intrathecal injection of 2.5ml of bupivacaine (0.5%) 
and 0.5 ml of normal saline at lumbar segments 3-4 (L3-L4) 
or 4-5 (L4-L5), using 25-gauge needles (B-Braun Co.). After 
placing the patients in a supine position, all of them received 
a venturi mask with an oxygen flow between 5-6 ml per 
minute. In addition, 1/1-2 mg of intravenous midazolam, as a 
sedative, was administered. Both the patient and outcome 
assessor were blind to the type of administering intrathecal 
drug.  
Hemodynamic parameters of the patient in the 0 
(baseline), 5th, 10th, 15th, 30th, 60th, and 120th minutes and 
6th, 12th, 18th, and 24th hours were measured and recorded. 
Patients with systolic blood pressure < 90 received 5-10 mg 
of ephedrine. Moreover, patients with HR < 60 per minute 
received 0.5 mg of atropine.  
During surgery and recovery, the patients were examined 
and were categorized in terms of shivering, which was 
graded as follows: 0 = no shivering, 1= piloerection or 
peripheral vasoconstriction, but no visible shivering, 2= 
shivering in only one muscle group, 3= shivering in more 
than one muscle group but not generalized, and 4 = 
generalized shivering involving the whole body. Patients 
with extreme and generalized shivering (grade 4) were 
treated with pethidine 25 mg. In addition, patients were 
graded between 0-10 over 24 hours after the surgery in terms 
of postoperative onset and severity of pain was based on a 
visual analog scale (VAS).  
The VAS pain grading system is as follows: 0 = without 
pain, 1-2 = slight pain, 3-4 = mild pain, 5-6 = moderate pain, 
7-8 = severe pain and 9-10 = the worst pain. If pain grade of 
a patient was greater than 4 and/or the patient ask for 
analgesics because of having pain, pethidine 0.5 mg per 
kilogram body weight (maximum dose=30 mg) was 
administered. Additionally, patients were investigated in 
terms of nausea and vomiting over 24 hours after the 
surgery.  
Intravenous metoclopramide 10 mg was administered to 
patients with such problems. In this study, severity of pain at 
different times and average duration of the onset of pain as 
primary outcomes and shivering, nausea, and vomiting post 
operation as secondary outcomes were recorded. Patients lost 
to follow-up were excluded from the study completely. Data 
were analyzed using chi-square test, Fisher’s exact test, t-
test, Mann-Whitney U test, and repeated measures in SPSS 
16. Furthermore, p<0.05 was considered to be significant.  
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Results  
This study was conducted on 100 patients, who were 
equally divided into dexmedetomidine plus bupivacaine and 
bupivacaine groups. There were 40 (80%) women and 10 
(20%) men in the bupivacaine group and 22 (44%) women 
and 28 (56%) men in the dexmedetomidine group (figure 1).  
 
 
 
Figure 1. Consort flowchart 
 
The mean and standard deviation of other demographic 
characteristics of the patients in both groups are presented in 
table 1. According to tables 2-5, hemodynamic parameters 
may be statistically but not clinically significant in the 
beginning or some other times, and changes are less than 
20% of the baseline. The mean and standard deviation of 
oxygen saturation of the patients at different times are 
presented in table 5. 
The mean and median of severity of pain at different 
times for both groups is presented in table 6. Average  
duration of the onset of pain in the bupivacaine group was  
 
230±86 minutes, which was significantly lower than the 
dexmedetomidine+bupivacaine group with the mean of 
495±138 (p=0.000). Moreover, 40 (80%) patients in the 
bupivacaine group and 39 (78%) patients in the 
dexmedetomidine+bupivacaine group received pethidine 
(p>0.05). 
 The mean pethidine intake in the bupivacaine group and 
dexmedetomidine+bupivacaine group was 87.5 mg and 33.6 
mg, respectively (P=0.000).  
The shivering, nausea, and vomiting conditions of the 
patients in both groups are presented in table 6. The mean 
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severity of shivering in the bupivacaine group and 
dexmedetomidine+bupivacaine group was 1.4 and 0.9, 
respectively (P=0.377). Moreover, eight patients in the 
bupivacaine group received pethidine for shivering 
treatment. Eighteen patients in the bupivacaine group and 12 
patients in the dexmedetomidine+bupivacaine group 
received metoclopramide 10 mg as an antiemetic (P=0.257). 
Nineteen patients in the dexmedetomidine+bupivacaine 
group had nausea and vomiting, out of which seven patients 
had mild nausea and did not need treatment; whereas, all 18 
patients in the bupivacaine group received metoclopramide 
for having severe nausea and vomiting. 
 
Table 1. Mean and standard deviation of demographic information of patients in both groups 
 
Group 
variable 
Bupivacaine 
(50 patients) 
Dexmedetomidine+bupivacaine 
(50 patients) 
P-value* 
Age (year) 44.4±14.5 44.3±13 0.977 
Height (cm) 169±7.8 171.9±6.8 0.048 
Weight (kg) 72.1±12.1 73.3±5.4 0.547 
BMI (Kg/m3) 25.2±4.3 24.9±2.1 0.626 
                                                BMI: Body mass index         *Independent sample t-test 
 
Table 2. Mean and standard deviation of heart rate in both groups 
 
Group 
time 
Bupivacaine 
(50 patients) 
Dexmedetomidine 
+bupivacaine 
(50 patients) 
Mean difference CI 95% P-value* 
Lower Upper 
Zero 79.4±18.5 88.6±10.4 -9.2 -15.1 -3.2 0.003 
5th minute 76.4±18.1 85.4±11.6 -9.0 -15.0 -2.9 0.004 
10th minute 74.4±17.1 75.8±8.2 -1.4 -6.7 3.9 0.605 
15th minute 72.7±16.9 69.7±8.8 3.0 -2.3 8.3 0.27 
30th minute 71.4±16.1 69.7±8 4.3 -0.7 9.3 0.096 
60th minute 69.4±12.5 67.8±6.5 1.6 -2.3 5.6 0.409 
120th minute 70.7±12 68.2±5.9 2.5 -1.2 6.2 0.193 
6th hour 74.6±7.8 70.8±5.2 3.7 1.0 6.3 0.006 
12th hour 74.3±5.7 73.2±5.4 1.1 -1.1 3.3 0.328 
18th hour 72.2±6.6 74.1±4.4 -1.9 -4.1 0.3 0.097 
24th hour 76.4±5.2 74.7±5.9 1.7 -0.5 3.9 0.128 
P-value 0.001 0.000   
                       *Independent sample t-test 
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Table 3. Mean and standard deviation of systolic blood pressure in both groups 
Group 
time 
Bupivacaine 
(50 patients) 
Dexmedetomidine 
+bupivacaine 
(50 patients) 
Mean difference 
CI 95% 
P-value* 
Lower Upper 
Zero 139.1±13.7 147.1±14.1 -8.0 -13.5 -2.4 0.005 
5th minute 127.9±15 137.8±12.5 -9.9 -15.4 -4.4 0.001 
10th minute 122.6±14.7 129.4±10.1 -6.8 -11.8 -1.7 0.009 
15th minute 115.7±16.1 122.7±10.7 -7.0 -12.4 -1.5 0.012 
30th minute 115±16 117.5±11.6 -2.4 -8.0 3.0 0.379 
60th minute 115.4±15.1 118.2±7.8 -2.8 -7.6 1.9 0.236 
120th minute 115.7±12.2 118.9±7.6 -3.1 -7.2 0.8 0.124 
6th hour 122±10.8 124.3±8.5 -2.2 -6.1 1.5 0.246 
12th hour 124.2±13.3 128±8.1 -3.7 -8.1 0.6 0.094 
18th hour 123.3±13.9 129±9.3 -5.6 -10.3 -0.9 0.019 
24th hour 126.1±13.6 129.3±7.8 -3.1 -7.5 1.2 0.159 
P-value 0.000 0.000   
                      *Independent sample t-test 
Table 4. Mean and standard deviation of diastolic blood pressure in both groups 
Group 
time 
Bupivacaine 
(50 patients) 
Dexmedetomidine+bupivacaine 
(50 patients) 
Mean Difference 
CI 95% 
P-value* 
Lower Upper 
Zero 88.2±8.9 81.4±9 6.7 3.1 10.2 0.000 
5th minute 79.4±11.9 76.2±8.6 3.2 -0.9 7.3 0.126 
10th minute 74.8±11.7 72.2±7.9 2.6 -1.3 6.6 0.192 
15th minute 71.9±11.9 68.6±8.1 3.3 -0.7 7.3 0.105 
30th minute 71.4±13.5 65.6±7.8 5.9 1.4 10.3 0.009 
60th minute 71±11.9 64.6±6.1 6.3 2.5 10.1 0.001 
120th minute 71.3±8.7 64.3±6.1 6.9 3.9 9.9 0.000 
6th hour 73.4±9.1 67.2±5.6 6.1 3.1 9.1 0.000 
12th hour 75±8.3 69±6 6.0 3.1 8.9 0.000 
18th hour 74.3±9.1 69±7 5.3 2.0 8.5 0.002 
24th hour 76.8±9.2 70.8±6.9 6.1 2.9 9.4 0.000 
P-value 0.000 0.000   
           *Independent sample t-test 
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Table 5. Mean and standard deviation of oxygen saturation in both groups 
Group 
time 
Bupivacaine 
(50 patients) 
Dexmedetomidine+bupivacaine 
(50 patients) 
Mean difference 
CI 95% 
P-value* 
Lower Upper 
Zero 99.2±1.2 97.8±0.8 1.3 0.9 1.7 0.000 
5th minute 99.4±0.9 99.5±0.5 -.1 -0.4 0.2 0.527 
10th minute 99.5±0.7 99.4±0.7 0.0 -0.2 0.3 0.58 
15th minute 99.6±0.5 99.4±0.7 0.2 -0.0 0.5 0.075 
30th minute 99.6±0.7 99.2±0.7 0.4 0.1 0.6 0.009 
60th minute 99.2±0.9 99±0.8 0.1 -0.1 0.5 0.3 
120th minute 98.6±0.9 98.1±0.9 0.4 0.0 0.8 0.014 
6th hour 97.9±0.9 97.7±0.8 0.2 -0.1 0.6 0.161 
12th hour 97.7±0.9 97.4±0.8 0.2 -0.1 0.5 0.166 
18th hour 97.6±0.8 97.5±0.7 0.1 -0.2 0.4 0.524 
24th hour 97.7±0.6 97.4±0.6 0.3 0.1 0.5 0.018 
P-value 0.000 0.000   
             *Independent sample t-test 
 
Table 6. Shivering, nausea, and vomiting conditions of patients in both groups 
 Group Bupivacaine 
Number (%) 
Dexmedetomidine+bupivacaine 
Number (%) 
P-value* 
Shivering Without 14(28) 7(14) 0.14 
With 36(72) 43(86) 
Nausea and vomiting Without 32(64) 31(62) 1 
With 18(36) 19(38) 
                       *Chi-square 
Discussion 
The use of dexmedetomidine as a local anesthetic 
adjuvant has been increasingly reported to extend the 
duration of both motor and sensory blockade produced by 
single Injection neuraxial. (1, 3). The present study was 
conducted to determine the effect of intrathecal 
administration of dexmedetomidine plus bupivacaine on 
analgesia in lower abdominal surgery. The results showed 
that the mean duration of analgesia was significantly longer 
in dexmedetomidine plus bupivacaine group than in the 
bupivacaine group. As a result, adding dexmedetomidine 
prolongs the duration of analgesia after surgery.  
Based on VAS, the severity of pain in all investigated 
periods after the onset of pain was significantly lower in the 
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dexmedetomidine plus bupivacaine group than in the 
bupivacaine group. In a study conducted by Kaya FN et al. 
in Turkey on 75 ASA I and II patients undergoing spinal 
anesthesia with bupivacaine, patients were randomly divided 
into three groups. The first, second, and third groups 
received intravenous dexmedetomidine, midazolam, and 
intravenous normal saline before spinal anesthesia, 
respectively. The results showed that the intravenous 
administration of dexmedetomidine could increase the 
duration of bupivacaine block, sedation, and analgesia (10). 
In a study in India on 60 ASA I- II patients, aged 18-50 
years, undergoing lower abdominal surgery, Goupta et al. in 
2011 divided the patients into two groups. The first group 
received intrathecal bupivacaine plus fentanyl, and the 
second group received intrathecal 
bupivacaine+dexmedetomidine. On average, patients in the 
dexmedetomidine group had significantly longer motor and 
sensory block than those in the fentanyl group (3). In a study 
conducted by Shukla et al. in India on 90 ASA I and II 
patients, aged 18-45 years, undergoing lower abdominal and 
lower limb surgeries, patients were randomly divided into 
three groups. The first, second, and third groups received 
bupivacaine plus dexmedetomidine, bupivacaine plus 
magnesium sulfate, and bupivacaine diluted by saline, 
respectively. The results showed that the onset and duration 
of motor and sensory block were longer in the 
dexmedetomidine group than in the other two groups (2). Al-
Mustafa et al. in 2008 conducted a study in Jordan on 66 
patients undergoing urologic surgery. In their study, the 
patients were divided into three groups. The first, second, 
and third groups received bupivacaine 12.5mg and normal 
saline, bupivacaine 12.5 mg plus dexamethasone 5μg, and 
bupivacaine 12.5 mg besides dexamethasone 10 μg, 
respectively. The results showed that intrathecal 
dexmedetomidine shortened the onset of motor block and 
prolonged the regression of motor and sensory block (11).  
Consistent with similar studies, the present clinical trial 
showed that the intrathecal administration of 
dexmedetomidine could prolong the onset of postoperative 
pain. Moreover, the intrathecal administration of 
dexmedetomidine reduced the severity of pain in the case 
group as compared to the control group. 
The results showed that despite significant differences 
between the two groups in examining hemodynamic 
parameters, such as HR, BP, and OS, in some points of time, 
they followed a normal decreasing trend. Moreover, the 
hemodynamic decreasing trend (HR and BP) during the 
examined period was greater in the dexmedetomidine group 
than in the dexmedetomidine+bupivacaine group, but not 
significantly. This difference may be due to the inherent 
effect of dexmedetomidine (12). Kanazi et al. conducted a 
study in Lebanon on 60 ASA I and II patients who 
underwent prostate surgery and had bladder tumor. Patients 
were divided into three groups using double-blind method. 
The first, second, and third groups received bupivacaine plus 
dexmedetomidine, bupivacaine plus clonidine, and 
bupivacaine alone, respectively. It was observed that 
dexmedetomidine+clonidine could increase the duration of 
sensory and motor block of bupivacaine, without causing a 
drastic change in hemodynamic parameters of the patients 
(4). AL-Mustafa et al. conducted a study in Jordan on 48 
patients undergoing spinal surgery with isobaric 
bupivacaine. They observed that the intravenous 
administration of dexmedetomidine could increase the 
duration of sensory and motor block of intrathecal 
bupivacaine while hemodynamic stability had been 
maintained (13). The present study showed that intrathecal 
dexmedetomidine could not cause significant changes in 
hemodynamic parameters. 
Also, the dexmedetomidine+bupivacaine and 
bupivacaine groups were not significantly different in terms 
of shivering; however, it was more severe in the bupivacaine 
group, so the eight subjects in this group (versus no subject 
in the dexmedetomidine plus bupivacaine group) needed 
treatment. Burhanettin Usta et al. in 2011 designed a study in 
Turkey on 60 ASA I and II patients, aged 18-50 years, 
undergoing elective minor surgeries under spinal anesthesia. 
The patients were randomly divided into two groups. The 
first and the second groups received intravenous 
dexmedetomidine and intravenous normal saline, 
respectively. It was observed that dexmedetomidine could 
significantly reduce shivering in spinal anesthesia without 
causing any significant complication (14). 
The postoperative nausea and vomiting conditions in the 
two groups were not significantly different; although, fewer 
patients in the dexmedetomidine group needed 
metoclopramide treatment. Massad et al. conducted a study 
on 81 ASA I patients undergoing laparoscopy. Their results 
showed that adding dexmedetomidine significantly reduced 
the incidence of postoperative nausea and vomiting (15). 
In Conclusion, Administration of dexmedetomedine through 
the intrathecal route by acting as an adjuvant drug to local 
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anesthetics provided an analgesic effect in postoperative pain 
without sedation. It could potentiate the effect of the local 
anesthetic and allow a decrease in the required doses. The 
present study showed that dexmedetomidine in addition to 
local anesthetics could prolong the duration of both sensory 
and motor blockade and postoperative pain management 
without causing a significant clinical change in patients’ 
hemodynamic conditions. 
Limitations of this study: 
Trying to gather the exact data in close monitoring during 
surgery and unreliable patient's information were the major 
limitations of this study, while this trial like other trials could 
be influenced by experimenter bias, straw man comparison, 
unsuccessful randomization and composite outcomes as 
potential limitations of all clinical trial. 
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